Synonym
BRN4277924; BRN-4277924; BRN 4277924; Spirapril; Spiraprilum; Espirapril; Spirapril HCl; Spirapril hydrochloride
IUPAC/Chemical Name
(S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid hydrochloride
InChi Key
CLDOLNORSLLQDI-OOAIBONUSA-N
InChi Code
InChI=1S/C22H30N2O5S2.ClH/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27;/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27);1H/t15-,17-,18-;/m0./s1
SMILES Code
O=C([C@H](C1)N(C([C@H](C)N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)=O)CC31SCCS3)O.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
CAS#83647-97-6 (Spirapril free base)
CAS#94841-17-5 ( Spirapril HCl)
CAS#200872-06-6 (Spirapril hydrochloride monohydrate)
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| Soluble in DMSO, not in water |
0.0 |
100.00 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
503.07
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation for in vivo study
1: Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F. Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol Int. 2013 Mar;30(1-2):280-314. doi: 10.3109/07420528.2012.709448. Epub 2012 Oct 19. Review. PubMed PMID: 23077971.
2: Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am J Hypertens. 2011 Apr;24(4):383-91. doi: 10.1038/ajh.2010.217. Epub 2010 Oct 7. Review. PubMed PMID: 20930708.
3: Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. Review. PubMed PMID: 11929321.
4: Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001 May 16;48(1):115-36. Review. PubMed PMID: 11325479.
5: Elliot HL. [The ACE inhibitor spirapril in chronic renal failure, hypertension and diabetic nephropathy]. Ter Arkh. 2000;72(10):78-82. Review. Russian. PubMed PMID: 11220886.
6: Ding PY, Hu OY, Pool PE, Liao W. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? J Hum Hypertens. 2000 Mar;14(3):163-70. Review. PubMed PMID: 10694829.
7: Jardine AG, Elliott HL. ACE inhibition in chronic renal failure and in the treatment of diabetic nephropathy: focus on spirapril. J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 1:S31-4. Review. PubMed PMID: 10499562.
8: Hayduk K, Kraul H. Efficacy and safety of spirapril in mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1999 Aug;34 Suppl 1:S19-23. Review. PubMed PMID: 10499560.
9: Fischler MP, Follath F. [Comparative evaluation of ACE inhibitors: which differences are relevant?]. Schweiz Med Wochenschr. 1999 Jul 27;129(29-30):1053-60. Review. German. PubMed PMID: 10464907.
10: Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens. 1999 Jan-Feb;21(1-2):167-79. Review. PubMed PMID: 10052652.
11: Noble S, Sorkin EM. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Drugs. 1995 May;49(5):750-66. Review. PubMed PMID: 7601014.
12: Dahlöf B. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press Suppl. 1994;2:35-40. Review. PubMed PMID: 8061844.
13: Elliott HL. Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment. Blood Press Suppl. 1994;2:31-4. Review. PubMed PMID: 8061843.
14: Jerie P, Kremer HJ. Renpress, Sandopril (Spirapril/TI 211-950). Summary of chemical, pharmacological and clinical properties. Cor Vasa. 1992;34(1):82-7. Review. PubMed PMID: 1288944.
15: Salvetti A. Newer ACE inhibitors. A look at the future. Drugs. 1990 Dec;40(6):800-28. Review. PubMed PMID: 2078997.
16: McAreavey D, Robertson JI. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs. 1990 Sep;40(3):326-45. Review. PubMed PMID: 2226219.
